← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Callisto Pharmaceuticals, Inc.
New York, NY
$2,627,058
Total funding
7
Grants
Funding over time
peak $510.6K · FY2005–06$1M$750K$500K$250K$0
'05
'06
Funding mix
By agency
NIH$2,627,058 · 7
By mechanism
R41$1,547,427 · 4
U01$876,831 · 1
R43$202,800 · 2
Investigators at Callisto Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
New hepatitis B small molecule inhibitors$590,721
R41 · FY2002 · AI
Peptide &antibodies as antidotes for superantigens$510,620
U01 · FY2005 · AI
New hepatitis B small molecule inhibitors$369,228
R41 · FY2001 · AI
Peptide & antibodies as antidotes for superantigens$366,211
U01 · FY2006 · AI
Atiprimod to Treat Multiple Myeloma and Bone Resorption$265,697
R41 · FY2003 · CA
Iminosugars for treatment of antitrypsin deficiency$223,864
R41 · FY2001 · DK
Agonists of guanylate cyclase receptor for colon cancer$104,800
R43 · FY2002 · CA
Cloning, expression and purification of uroguanylin$98,000
R43 · FY2002 · CA
MUTATION 'REFRACTION'BROAD SPECTRUM ANTI-HEPATITIS DRUG$97,917
R41 · FY2000 · GM